Cogent BiosciencesCOGT
Recorded

Cogent Biosciences Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Faisal KhurshidSenior Biotech Analyst

All right. Good afternoon, or I guess soon to be evening here in London, everyone. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today the management team of Cogent Bio. On stage with me is Andy Robbins. Andy, can I ask you to briefly introduce the company, please?

Andrew RobbinsPresident and CEO

Sure. First of all, thanks, Faisal, for inviting us. We are happy to be here in London and meeting a great lineup of investors today. For those who are not familiar with our story, Cogent Biosciences is a company that is focused on the development of small molecule kinase inhibitors for patients with rare genetically driven diseases. Our lead asset is a drug known as bezuclastinib. It is a selective potent KIT inhibitor being developed for three distinct patient populations, the advanced and non-advanced forms of systemic mastocytosis, as well as imatinib-resistant gastrointestinal stromal tumors. Each of those patient populations, we ran a pivotal trial culminating with the results in 2025. All three were very positive with signs for high utility for use commercially in those patient groups.

Andrew RobbinsPresident and CEO

We have spent most of 2026 submitting NDAs and then working with the FDA on pending PDUFA action dates of November 30th, December 30th, and June 29th of 2027 for GIST, non-advanced, and advanced, in that order. We are very excited. The other thing we have been doing this past year is preparing to launch the drug, so adding a number of commercial colleagues to the company, transitioning Cogent from a research and development organization into a fully integrated biopharmaceutical company. We are now very, very ready to launch the drug when we get the word from the FDA, and hopefully bring bezuclastinib to many, many patients in need of a new therapeutic. Maybe I will pause there and see where you want to go next.

Faisal KhurshidSenior Biotech Analyst

All right, great. Andy, we are kind of sitting here not too far away from your PDUFA date for GIST. Can you just give us an update to the extent possible on where things stand?

Andrew RobbinsPresident and CEO

Yeah, we don't typically comment on the specific details of any discussions with regulatory agencies, so we'll wait until we get an approval. But we're expecting it. As I think folks may know, we're being reviewed under both Breakthrough Therapy Designation and Real-Time Oncology Review. The data from the PEAK study were about as unequivocal as you can get in a large phase III cancer trial with a hazard ratio of 0.50 on the primary endpoint, with 16 and a half month estimate for median progression-free survival relative to just over nine months for the control arm, and a nearly doubling of objective response rate. The other really important part of the findings is that we showed that the average duration of therapy for patients on the combination now exceeds 21 months.

Andrew RobbinsPresident and CEO

That is relative to the expectation prior to the PEAK study in second-line GIST of about a seven or an eight-month average duration of therapy. So this combination of bezuclastinib with sunitinib can really provide significant long-term benefit to patients.

Faisal KhurshidSenior Biotech Analyst

Got it. So Andy, you know we got to talk about this. Investors have gotten kind of jittery about this idea of liver toxicity and what kind of warning language could come onto the label. Can you level set us on your expectations based on the data that we have today?

Andrew RobbinsPresident and CEO

Yeah. Well, we can tell you, and I've said this a few times, bezuclastinib, I think, is a very, at this point, very carefully and thoroughly characterized safety profile. When you look across our studies, whether you look at the SUMMIT study at 100 milligram daily dose in non-advanced patients all the way up to the PEAK study using 600 milligrams of the same molecule in metastatic cancer patients with GIST, you see a very consistent safety profile where in sort of the order of the most frequent reported adverse events, some patients experience changes in salty flavors as a taste. The next most prevalent adverse event would be their hair turning white, which is a very well-known characterized effect of an on-target KIT inhibitor. And then the most frequent adverse event, and in our case always reported as lab abnormalities, are fluctuating or elevated transaminases.

Andrew RobbinsPresident and CEO

What's most important in this profile is we are not associated with significant clinical sequelae in response to the elevated transaminases. We don't have any patients with liver failure, liver transplant, any serious liver clinical adverse events, no Hy's Law. This truly, the profile is of fluctuating transaminases, and in all cases, the patients that have been treated with bezuclastinib, whether without any intervention, whether with dose reduction, or in very rare cases with dose discontinuation, have returned to baseline levels of transaminases. That's the profile. We are happy to stipulate that patients who are initiated on bezuclastinib should have liver monitoring. They should be tested with blood labs across these indications. It is the responsible thing to do. We also have talked to all oncologists, hematologists, complex allergists who treat patients across these three indications.

Andrew RobbinsPresident and CEO

They all expect this as well and see no barrier to prescribing based on that profile.

Faisal KhurshidSenior Biotech Analyst

Got it. Then with respect to specifics on the label itself, based on kind of your understanding of the profile you have and FDA precedent, would you expect this to be a situation where this is elevated to a black box warning, or is it something that would more likely sit in the warnings and precautions?

Andrew RobbinsPresident and CEO

It's hard to predict until we have a final label, but if you're talking specifically about GIST, where our drug will be approved in combination with sunitinib, which has been the standard of care for the last 20 plus years around the world for second-line GIST patients. We politely point out that sunitinib itself has monitoring language, which suggests monthly monitoring for transaminase elevations, along with a box warning with, I would say, fairly substantial language relative to sunitinib. That did not dissuade oncologists and sarcoma experts around the world from establishing it as the standard of care for these patients. I don't know the answer specifically to your question of what will happen, but we know that the standard of care currently includes a box warning for hepatotoxicity with monitoring, and it is widely adopted in all patients coming off of imatinib resistance.

Faisal KhurshidSenior Biotech Analyst

Got it. With respect to just this kind of regulatory question, you do point out that sunitinib does have a black box warning and this monitoring requirement for transaminases. Is there a precedent of a black box warning of the combo partner coming on to a new drug that's approved with that? Are there examples of the opposite? What does the precedent tell us here?

Andrew RobbinsPresident and CEO

Yeah. We've done some work. You can find cases for both of the questions you've asked, where it appears in labeling that a drug which is approved for the first time only in combination with another drug has some warnings and precaution or adverse event language brought over from the drug that it's approved in combination with. You can also easily find cases where that's not the case. There doesn't seem to be a hard and fast rule from the FDA about how they apply this. I think that they look at the totality of the evidence from a clinical setting. They look at risk-benefit for the patient population. They probably look at a number of other factors. Most importantly, the individuals who are doing the review in different divisions of the FDA probably have different standards of how they apply this.

Andrew RobbinsPresident and CEO

I wish that there was a rule in the CFR that told you exactly what's going to happen, but I don't think there is one.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day